Primary relevance to vitamin D Vitamin D is a stated subject of this paper.
Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.
Why this paper is included
Supporting source evidence:
In the unadjusted model, we found no evidence of an effect of vitamin D3 supplementation relative to placebo [hazard ratios (HRs) (95% confidence intervals, CIs): 1000 IU/day 0.87 (0.50, 1.50); 5000 IU/day 1.37 (0.82, 2.29); 10 000 IU/day 1.28 (0.76, 2.14)] on risk of conversion to MS.
Source: Intention to treat analysis. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Randomised controlled trial.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Meta-analysis unclear · Double-blind reported · Human research reported
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
We conducted a double-blind trial in Australia and New Zealand.
Source: Abstract.
This phase IIb randomized double-blind placebo-controlled trial compared daily oral doses of vitamin D3 [either 1000, 5000, or 10 000 international units (IU)] to placebo in adult CIS cases with a high risk of conversion to MS.
Source: Methods.
All supplement supplies were delivered to a central pharmacy in temperature-controlled transport with monitoring (with no significant violation of temperature controls), and participants were asked to store the trial supplement at <25°C.
Source: Methods.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Vitamin D did not reduce multiple sclerosis disease activity after a clinically isolated syndrome
Randomised controlled trial · Brain · 2024
Original publication title
Vitamin D did not reduce multiple sclerosis disease activity after a clinically isolated syndrome
© The Author(s) 2023. Published by Oxford University Press on behalf of the Guarantors of Brain.
Original publication · Publisher record · CC BY 4.0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
What does the authors’ abstract report?
Abstract
Low serum levels of 25-hydroxyvitamin D [25(OH)D] and low sunlight exposure are known risk factors for the development of multiple sclerosis. Add-on vitamin D supplementation trials in established multiple sclerosis have been inconclusive. The effects of vitamin D supplementation to prevent multiple sclerosis is unknown.
We aimed to test the hypothesis that oral vitamin D3 supplementation in high-risk clinically isolated syndrome (abnormal MRI, at least three T2 brain and/or spinal cord lesions), delays time to conversion to definite multiple sclerosis, that the therapeutic effect is dose-dependent, and that all doses are safe and well tolerated.
We conducted a double-blind trial in Australia and New Zealand. Eligible participants were randomized 1:1:1:1 to placebo, 1000, 5000 or 10 000 international units (IU) of oral vitamin D3 daily within each study centre (n = 23) and followed for up to 48 weeks. Between 2013 and 2021, we enrolled 204 participants. Brain MRI scans were performed at baseline, 24 and 48 weeks.
The main study outcome was conversion to clinically definite multiple sclerosis based on the 2010 McDonald criteria defined as either a clinical relapse or new brain MRI T2 lesion development.
We included 199 cases in the intention-to-treat analysis based on assigned dose. Of these, 116 converted to multiple sclerosis by 48 weeks (58%). Compared to placebo, the hazard ratios (95% confidence interval) for conversion were 1000 IU 0.87 (0.50, 1.50); 5000 IU 1.37 (0.82, 2.29); and 10 000 IU 1.28 (0.76, 2.14). In an adjusted model including age, sex, latitude, study centre and baseline symptom number, clinically isolated syndrome onset site, presence of infratentorial lesions and use of steroids, the hazard ratios (versus placebo) were 1000 IU 0.80 (0.45, 1.44); 5000 IU 1.36 (0.78, 2.38); and 10 000 IU 1.07 (0.62, 1.85).
Vitamin D3 supplementation was safe and well tolerated.
We did not demonstrate reduction in multiple sclerosis disease activity by vitamin D3 supplementation after a high-risk clinically isolated syndrome.
Low serum vitamin D levels are a known risk factor for the development of multiple sclerosis. However, in a randomized controlled trial, Butzkueven et al. found that daily oral vitamin D3 supplements did not delay the conversion of high-risk clinically isolated syndrome to clinically definite multiple sclerosis.
Authors’ abstract
Abstract
Low serum levels of 25-hydroxyvitamin D [25(OH)D] and low sunlight exposure are known risk factors for the development of multiple sclerosis. Add-on vitamin D supplementation trials in established multiple sclerosis have been inconclusive. The effects of vitamin D supplementation to prevent multiple sclerosis is unknown.
We aimed to test the hypothesis that oral vitamin D3 supplementation in high-risk clinically isolated syndrome (abnormal MRI, at least three T2 brain and/or spinal cord lesions), delays time to conversion to definite multiple sclerosis, that the therapeutic effect is dose-dependent, and that all doses are safe and well tolerated.
We conducted a double-blind trial in Australia and New Zealand. Eligible participants were randomized 1:1:1:1 to placebo, 1000, 5000 or 10 000 international units (IU) of oral vitamin D3 daily within each study centre (n = 23) and followed for up to 48 weeks. Between 2013 and 2021, we enrolled 204 participants. Brain MRI scans were performed at baseline, 24 and 48 weeks.
The main study outcome was conversion to clinically definite multiple sclerosis based on the 2010 McDonald criteria defined as either a clinical relapse or new brain MRI T2 lesion development.
We included 199 cases in the intention-to-treat analysis based on assigned dose. Of these, 116 converted to multiple sclerosis by 48 weeks (58%). Compared to placebo, the hazard ratios (95% confidence interval) for conversion were 1000 IU 0.87 (0.50, 1.50); 5000 IU 1.37 (0.82, 2.29); and 10 000 IU 1.28 (0.76, 2.14). In an adjusted model including age, sex, latitude, study centre and baseline symptom number, clinically isolated syndrome onset site, presence of infratentorial lesions and use of steroids, the hazard ratios (versus placebo) were 1000 IU 0.80 (0.45, 1.44); 5000 IU 1.36 (0.78, 2.38); and 10 000 IU 1.07 (0.62, 1.85).
Vitamin D3 supplementation was safe and well tolerated.
We did not demonstrate reduction in multiple sclerosis disease activity by vitamin D3 supplementation after a high-risk clinically isolated syndrome.
Low serum vitamin D levels are a known risk factor for the development of multiple sclerosis. However, in a randomized controlled trial, Butzkueven et al. found that daily oral vitamin D3 supplements did not delay the conversion of high-risk clinically isolated syndrome to clinically definite multiple sclerosis.
Publication and source details
Original title: Vitamin D did not reduce multiple sclerosis disease activity after a clinically isolated syndrome
Helmut Butzkueven; Anne-Louise Ponsonby; Mark S Stein; Robyn M Lucas; Deborah Mason; Simon Broadley; Trevor Kilpatrick; Jeannette Lechner-Scott; Michael Barnett; William Carroll; Peter Mitchell; Todd A Hardy; Richard Macdonell; Pamela McCombe; Andrew Lee; Tomas Kalincik; Anneke van der Walt; Chris Lynch; David Abernethy; Ernest Willoughby; Frederik Barkhof; David MacManus; Michael Clarke; Julie Andrew; Julia Morahan; Chao Zhu; Keith Dear; Bruce V Taylor; the PREVANZ Investigators GebskiValKimberThomasBarberAlanWraightPaulSampangiSandeepAliRashidaMillerDavidKruppLaurenChurilovLeonidChingMichaelHodkinsonSusanneButlerErnieShawCameronFraserClaireMottersheadJohn
Brain · 2024
Correspondence to: Bruce V. Taylor Menzies Institute for Medical Research, University of Tasmania 17 Liverpool Street, Hobart, Tasmania 7000, Australia E-mail: bruce.taylor@utas.edu.au© The Author(s) 2023. Published by Oxford University Press on behalf of the Guarantors of Brain.2023https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. PREVANZRepository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T04:50:01.930101+00:00
DOI: 10.1093/brain/awad409 · PMC10994527